|
Description: Dentown Group is exclusively appointed to present the acquisition opportunity of a fully operational TGA GMP licensed pharmaceutical and nutraceutical manufacturing facility located in Auburn, Sydney.
This offering represents a rare opportunity to acquire an established GMP manufacturing platform together with its industrial property.
Property Overview
• Total building area: approx. 1,330 sqm
• Level 1 office & storage: approx. 550 sqm
• GMP production & warehouse: approx. 780 sqm
• Strata industrial complex with shared parking
Strategically positioned within Sydney’s established industrial and logistics corridor.
Business Overview:
- Established: June 2020
- Staff: 10
- TGA GMP Licensed Manufacturer
- Operating under PIC/S and Australian regulatory standards
- The business operates as a full-service contract manufacturer for natural health products and complementary medicines, supplying domestic and international markets.
Manufacturing Capabilities:
Production formats include:
• Hard Capsules
• Soft Gel Capsules
• Tablets
• Powders
• Liquids
• Creams / Semi-Solids
• Sachet Packaging
• Bottling & Labelling
Indicative production capacity:
• Hard capsules: approx. 80,000 per hour
• Soft capsules: up to 95,000 per hour
• Tablets: up to 78,000 per hour
• Liquid filling: approx. 6,240 bottles per shift
• Bottling line: approx. 12,480 bottles per shift
Investment Highlights:
• Rare TGA GMP licensed manufacturing platform
• Immediate operational continuity
• Established customer relationships
• High regulatory barrier to entry
• Suitable for pharmaceutical groups, nutraceutical brands and cross-border operators
• Property also available for sale or lease
Mutual Recognition Advantage:
Australia’s GMP system participates in Mutual Recognition Agreements (MRA), enabling recognition by regulatory authorities in multiple jurisdictions including the UK, Canada, Singapore, New Zealand and several European countries.
This significantly facilitates international market access for products manufactured in Australia.
Strategic Value:
Acquiring an existing GMP facility significantly reduces the time, capital investment and regulatory complexity associated with new licence applications and facility development.
This opportunity provides a direct entry into the Australian regulated pharmaceutical and nutraceutical manufacturing sector.
property ID ：BUSI 202
|
Click here to format this page for printing
